Close Menu

NEW YORK – Caris Life Sciences said on Tuesday that it has raised $310 million in growth capital, including $235 million in equity financing and $75 million in debt financing.

The equity financing was co-led by Highland Capital Management and Coatue, with participation from funds and accounts advised by T. Rowe Price Associates, OrbiMed, Millennium Management, Neuberger Berman, ClearBridge Investments, First Light Asset Management, and undisclosed investors. The company noted that this is its first significant external equity investment.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.